IP Verse

Krka competitive analysis

Latest oppositions filed by Krka

Explore patent oppositions filed by Krka against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 3, 2026
Patent NumberTitleApplicantOpposition Date
EP2396005
Sglt-2 Inhibitor For Treating Type 1 Diabetes Mellitus, Type 2 Diabete Mellitus, Impaired Glucose Tolerance Or HyperglycemiaBOEHRINGER INGELHEIMAug 24, 2026
EP3689365
Use Of Long-Acting Glp-1 PeptidesNOVO NORDISKMay 6, 2026
EP4321157
New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTISJul 23, 2025
EP2818163
Composition For Nasal Application With Improved StabilityMARIA CLEMENTINE MARTIN KLOSTERFRAU VERTRIEBSGESELLSCHAFTMar 26, 2025
EP3294283
Sacubitril-Valsartan Dosage Regimen For Treating Heart FailureNOVARTISDec 8, 2023
EP3113774
Compositions Of Grapiprant And Methods For Using The SameARATANA THERAPEUTICSSep 21, 2022
EP2922526
Manufacturing Of Semi-Plastic Pharmaceutical Dosage UnitsINTERVETJul 26, 2022
EP2863895
Tablet Formulation Comprising A Peptide And A Delivery AgentNOVO NORDISKJan 14, 2022
EP3173071
Maropitant FormulationLE VETDec 23, 2021
EP2478907
Methods And Compositions For Treating CancerCOUGAR BIOTECHNOLOGYDec 22, 2021

Latest patents of Krka opposed by its competitors

Explore Krka's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 3, 2026
Patent NumberPublication DateTitleTotal Oppositions
EP2400954
Jun 26, 2024Process For Forming Solid Oral Dosage Forms Of Solifenacin And Its Pharmaceutically Acceptable Salts2
EP2588090
Nov 22, 2023Pharmaceutical Oral Dosage Forms Comprising Dabigatran Etexilate And Its Pharmaceutically Acceptable Salts4
EP3309158
Mar 16, 2022Crystalline Form K Of Rivaroxaban And Process For Its Preparation2
EP2459555
Nov 3, 2021Processes For Crystallization Of Rivaroxaban2
EP2585051
Apr 8, 2020Pharmaceutical Oral Dosage Forms Comprising Lercanidipine And Enalapril And Their Pharmaceutically Acceptable Salts1
EP2442799
May 22, 2019Solid Pharmaceutical Composition Comprising Rivaroxaban1
EP2398468
Nov 30, 2016Pharmaceutical Compositions Comprising Prasugrel Base Or Its Pharmaceutically Acceptable Acid Addition Salts And Processes For Their Preparation4
EP2931041
Nov 16, 2016Veterinary Composition For Dermal Application1
EP1729739
Sep 28, 2016Process For Preparing A Solid Pharmaceutical Composition2
EP2276347
May 25, 2016Toltrazuril With Improved Dissolution Properties1

Latest PTAB cases involving Krka

Discover the latest PTAB cases involving Krka, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Krka with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 3, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
KRKA3820 - -
BAYER42133 - -
BAYER ANIMAL HEALTH GMBH34 - -
BAYER HEALTHCARE - 41 - 1